CROs/Service Providers

Former Head of German CRO IMFORM Sentenced for Fraud, Corruption

Monday, September 11, 2006

Peter U. Witte, former president and chief executive officer of IMFORM, a contract research organization (CRO) based in Darmstadt, Germany, was sentenced in August to four years in jail in Munich District Court for fraud, corruption, and aiding and abetting the betrayal of confidence. CW Weekly has been investigating what led up to Witte’s sentencing for several months. Witte confessed that for years he had defrauded his principal client, Japan-based pharmaceutical company Sankyo, with bills for several million euros for services supposedly performed during a drug study, according to a published report in Süddeutsche Zeitung.

[Read More]

The Name Game

Monday, August 21, 2006

It’s a call I made in January. So what took SFBC so long to decide to change its name to PharmaNet? While the move took a little longer than expected, it is another sign that new CEO Jeffrey McMullen and his PharmaNet-ters still have a solid chance to turnaround the troubled former SFBC.

[Read More]

New Medical Device CRO Symbios Clinical Established

Monday, July 31, 2006

Symbios Clinical, a new contract research organization (CRO) based in Minnesota, has recently begun formal operations. The CRO focuses on the medical device industry. The company began with $500,000 in start-up financing. Co-founders Ethan Rooney and Ryan Wilson began the company after careers in the medical device sector, both working for large companies. During an interview conducted by CenterWatch, Ethan Rooney elaborated on the need for such a CRO in the medical device industry:

[Read More]

Averion Goes Public

Wednesday, July 19, 2006

The San Diego, Calif.-based company IT&E International, a regulatory compliance and validation services provider has agreed to merge with Averion, a contract research organization based in Framingham, Mass., for roughly $25 million, including $20 million of stock and notes and $5 million in cash. The new company will retain the Averion name, and allow Averion to become a publicly traded company.

[Read More]